Oppenheimer Maintains Outperform on Mindray Medical Int'l

Oppenheimer is out with its report today on Mindray Medical Int'l MR, maintaining Outperform. In a note to clients, Oppenheimer writes, "Management kept >16% top-line guidance unchanged assuming a 17-18% growth rate in China. We tweak our model slightly to reflect potential 2012 margin expansion and maintain our Outperform rating." Oppenheimer maintains a $32 PT on MR. Shares of MR closed Tuesday at $26.98, down 0.04% from Monday's close.